Literature DB >> 31350718

Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine.

Koichi Sato1, Tomoaki Suga2, Atsuhiro Hirayama1, Seiichi Daikuhara1, Takeshi Uehara3, Eiji Tanaka1.   

Abstract

A 52-year-old woman was treated for colorectal diffuse large B-cell lymphoma (DLBCL) after a prolonged treatment period of azathioprine (AZA) and infliximab (IFX) for Crohn's disease (CD). She had been diagnosed as having colonic CD at the age of 24 years and received AZA from age 29. IFX was added at 47 years of age. She experienced massive hematochezia and anal pain at the age of 52 years and was transferred to our hospital. Endoscopic examination revealed a deep rectal ulcer with arterial bleeding. A stoma constructed at the transverse colon for refractory CD relieved her symptoms. Four months later, computed tomography showed increased thickness of the rectal wall. DLBCL was diagnosed from biopsy specimens of the rectum. Treatment with 6 courses of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone along with additional radiation therapy for remnant rectal lymphoma has resulted in complete remission for over 5 years. Although colorectal malignant lymphoma coexisting with active CD was rare and the lesions were difficult to detect, intensive therapy for CD helped in the diagnosis and successful treatment of the patient.

Entities:  

Keywords:  Azathioprine; Crohn’s disease; Infliximab; Intestinal lymphoma

Year:  2019        PMID: 31350718     DOI: 10.1007/s12328-019-01026-1

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  15 in total

1.  European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.

Authors:  Vito Annese; Laurent Beaugerie; Laurence Egan; Livia Biancone; Claus Bolling; Christian Brandts; Daan Dierickx; Reinhard Dummer; Gionata Fiorino; Jean Marc Gornet; Peter Higgins; Konstantinos H Katsanos; Loes Nissen; Gianluca Pellino; Gerhard Rogler; Franco Scaldaferri; Edyta Szymanska; Rami Eliakim
Journal:  J Crohns Colitis       Date:  2015-08-20       Impact factor: 9.071

2.  Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.

Authors:  Shota Saito; Utako Shimizu; Zhang Nan; Nozomu Mandai; Junji Yokoyama; Kenshi Terajima; Kouhei Akazawa
Journal:  J Crohns Colitis       Date:  2012-05-22       Impact factor: 9.071

3.  Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.

Authors:  Lisa J Herrinton; Liyan Liu; Xiaoping Weng; James D Lewis; Susan Hutfless; James E Allison
Journal:  Am J Gastroenterol       Date:  2011-10-25       Impact factor: 10.864

4.  Safe use of infliximab for the treatment of severe perianal Crohn's disease after diagnosis and treatment of lymphoma.

Authors:  Carlos Bernardes; Pedro Russo; Diana Carvalho; Joana Saiote; Jaime Ramos
Journal:  Clin J Gastroenterol       Date:  2017-11-22

5.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

6.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab.

Authors:  Antonio López San Román; Manuel Van Domselaar; Miguel Rivero; Clara Redondo; Rosario Arribas; Antonio Rey
Journal:  J Crohns Colitis       Date:  2008-03       Impact factor: 9.071

8.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Authors:  Laurent Beaugerie; Nicole Brousse; Anne Marie Bouvier; Jean Frédéric Colombel; Marc Lémann; Jacques Cosnes; Xavier Hébuterne; Antoine Cortot; Yoram Bouhnik; Jean Pierre Gendre; Tabassome Simon; Marc Maynadié; Olivier Hermine; Jean Faivre; Fabrice Carrat
Journal:  Lancet       Date:  2009-11-07       Impact factor: 79.321

Review 9.  Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatment.

Authors:  David Laharie
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

10.  Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study.

Authors:  Tine Jess; Erzsébet Horváth-Puhó; Jan Fallingborg; Henrik H Rasmussen; Bent A Jacobsen
Journal:  Am J Gastroenterol       Date:  2013-08-27       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.